Asia Pacific Equity Research 10 June 2026 Innovent Biologics (1801) Overweight Impressive Next-Gen Obesity & Metabolic Pipeline at the ADA 2026 Innovent Biologics unveiled comprehensive pre-clinical and early clinical data for its next-generation obesity and metabolic pipeline at the 2026 ADA (American Diabetes Association) meeting. The portfolio demonstrates a strategic shift toward enhancing patient convenience and deepening efficacy through diverse mechanisms. Key assets include IBI3032, a novel oral GLP ...